Pipeline

A suite of localized immunostimulants.

Kinimmune is advancing a portfolio of programs to potentiate immunity in the solid tumor standard of care, spanning localized administration and systemic delivery. Select any program to see more.

Program
DiscoveryProof of ConceptLead OptimizationIND-enablingPhase I/II

Localized administration

Interventional immuno-oncology
Kinnate™ Series · Precision peptides for localized delivery
KIN-112Lead candidateNext-generation glatiramoid + TLR9 agonist
SeriesKinnate™ Series
AdministrationLocalized
StageLead Optimization
KIN-113Next-generation glatiramoid + PAMP
SeriesKinnate™ Series
AdministrationLocalized
StageDiscovery
Kinetokines™ · Engineered cytokines for localized delivery
KIN-201Undisclosed
SeriesKinetokines™
AdministrationLocalized
StageLead Optimization
KIN-202Undisclosed
SeriesKinetokines™
AdministrationLocalized
StageProof of Concept

Systemic administration

Versatile adjunct therapies
KIN-300 Series · Localization through systemic delivery
KIN-301Systemically localizing cytokine
SeriesKIN-300 Series
AdministrationSystemic
StageDiscovery
KIN-302Undisclosed
SeriesKIN-300 Series
AdministrationSystemic
StageDiscovery
KIN-112: glatiramoid amino-acid peptide complexed with a CpG TLR9 agonist forming a stable, tumor-retentive complex
Lead Product Candidate

KIN-112: Localized innate immune activation

Lead candidate

KIN-112 combines Kinimmune’s proprietary next-generation glatiramoid with a TLR9 agonist to form tissue-retentive complexes for localized administration. The program is designed to concentrate innate immune activation within tumor tissue, limit systemic exposure, and support broader antitumor immunity.

ModalityPeptide–TLR9 agonist complex
AdministrationLocalized
Development stageLead Optimization
Therapeutic focusSolid tumors
Explore the science behind KIN-112